Evolent Health (EVH) Cash & Current Investments (2015 - 2026)

Evolent Health has reported Cash & Current Investments for 12 years, with the latest figure at $166.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 36.84% year-over-year to $166.0 million; the trailing twelve-month figure through Mar 2026 stood at $166.0 million (down 36.84% YoY), and the FY2025 full-year result was $178.0 million, up 8.86% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $166.0 million, down from $178.0 million in the prior quarter.
• The five-year high for Cash & Current Investments was $267.4 million in Q2 2022, with the low at $112.9 million in Q3 2024.
• Average Cash & Current Investments over 5 years is $189.6 million, with a median of $181.8 million recorded in 2022.
• Year-over-year, Cash & Current Investments tumbled 45.64% in 2024 and jumped 44.57% in 2025.
• Tracing EVH's Cash & Current Investments over 5 years: stood at $202.7 million in 2022, then grew by 1.92% to $206.6 million in 2023, then fell by 20.86% to $163.5 million in 2024, then rose by 8.86% to $178.0 million in 2025, then retreated by 6.75% to $166.0 million in 2026.
• The last three Cash & Current Investments figures came in at $166.0 million (Q1 2026), $178.0 million (Q4 2025), and $140.3 million (Q3 2025), per Business Quant data.

Peer Comparison